Yousif Capital Management LLC Raises Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Yousif Capital Management LLC increased its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 22.4% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 14,325 shares of the company’s stock after acquiring an additional 2,622 shares during the period. Yousif Capital Management LLC’s holdings in Harmony Biosciences were worth $493,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its position in Harmony Biosciences by 92.6% in the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock worth $31,000 after acquiring an additional 436 shares during the period. Mendota Financial Group LLC grew its position in Harmony Biosciences by 24,125.0% in the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock worth $33,000 after acquiring an additional 965 shares during the period. CWM LLC grew its position in Harmony Biosciences by 111.7% in the third quarter. CWM LLC now owns 1,469 shares of the company’s stock worth $59,000 after acquiring an additional 775 shares during the period. KBC Group NV grew its position in Harmony Biosciences by 79.9% in the fourth quarter. KBC Group NV now owns 1,844 shares of the company’s stock worth $63,000 after acquiring an additional 819 shares during the period. Finally, Quantbot Technologies LP purchased a new position in shares of Harmony Biosciences during the third quarter worth $74,000. 86.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Harmony Biosciences

In other Harmony Biosciences news, CFO Sandip Kapadia sold 25,000 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $40.18, for a total value of $1,004,500.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Jeffrey Dierks sold 1,629 shares of the firm’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $38.02, for a total value of $61,934.58. The disclosure for this sale can be found here. Over the last three months, insiders sold 72,452 shares of company stock worth $2,831,679. Company insiders own 30.80% of the company’s stock.

Harmony Biosciences Trading Down 0.3 %

NASDAQ:HRMY opened at $38.98 on Monday. The firm has a market cap of $2.22 billion, a PE ratio of 18.47, a price-to-earnings-growth ratio of 0.51 and a beta of 0.80. The stock has a fifty day moving average price of $36.17 and a 200 day moving average price of $35.66. Harmony Biosciences Holdings, Inc. has a 12-month low of $28.14 and a 12-month high of $41.61. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on HRMY shares. HC Wainwright restated a “buy” rating and set a $75.00 price target on shares of Harmony Biosciences in a research report on Monday, January 27th. Needham & Company LLC restated a “buy” rating and set a $52.00 price target on shares of Harmony Biosciences in a research report on Monday, January 13th. Cantor Fitzgerald raised their price target on Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. Oppenheimer restated an “outperform” rating and set a $59.00 price target (up from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Harmony Biosciences in a research report on Tuesday, February 11th. They set a “buy” rating and a $55.00 price target for the company. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, Harmony Biosciences presently has a consensus rating of “Buy” and an average price target of $55.00.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.